Treev

En un mundo futurista, el cual estaba arruinado por el ser humano, sería abandonado. Años, décadas, SIGLOS de mal uso de los bienes proporcionados por la tierra, provocaron deforestación masiva la cual acabo con el 92% de la vegetación a nivel mundial, el 8% restante fue resguardado en bóvedas para “Repoblar” un planeta, un nuevo mundo, un reinicio, una nueva vida, este planeta fue llamado Treev (En memoria/referencia a Tree=Árbol)

The Imaging Magnetograph eXperiment (IMaX) for the Sunrise balloon-borne solar observatory

The Imaging Magnetograph eXperiment (IMaX) is a spectropolarimeter built by four institutions in Spain that flew on board the Sunrise balloon-borne telesocope in June 2009 for almost six days over the Arctic Circle. As a polarimeter IMaX uses fast polarization modulation (based on the use of two liquid crystal retarders), real-time image accumulation, and dual beam polarimetry to reach polarization sensitivities of 0.1%. As a spectrograph, the instrument uses a LiNbO3 etalon in double pass and a narrow band pre-filter to achieve a spectral resolution of 85 mAA. IMaX uses the high Zeeman sensitive line of Fe I at 5250.2 AA and observes all four Stokes parameters at various points inside the spectral line. This allows vector magnetograms, Dopplergrams, and intensity frames to be produced that, after reconstruction, reach spatial resolutions in the 0.15-0.18 arcsec range over a 50x50 arcsec FOV. Time cadences vary between ten and 33 seconds, although the shortest one only includes longitudinal polarimetry. The spectral line is sampled in various ways depending on the applied observing mode, from just two points inside the line to 11 of them. All observing modes include one extra wavelength point in the nearby continuum. Gauss equivalent sensitivities are four Gauss for longitudinal fields and 80 Gauss for transverse fields per wavelength sample. The LOS velocities are estimated with statistical errors of the order of 5-40 m/s. The design, calibration and integration phases of the instrument, together with the implemented data reduction scheme are described in some detail.Comment: 17 figure

Association Between Preexisting Versus Newly Identified Atrial Fibrillation and Outcomes of Patients With Acute Pulmonary Embolism

Background Atrial fibrillation (AF) may exist before or occur early in the course of pulmonary embolism (PE). We determined the PE outcomes based on the presence and timing of AF. Methods and Results Using the data from a multicenter PE registry, we identified 3 groups: (1) those with preexisting AF, (2) patients with new AF within 2 days from acute PE (incident AF), and (3) patients without AF. We assessed the 90-day and 1-year risk of mortality and stroke in patients with AF, compared with those without AF (reference group). Among 16 497 patients with PE, 792 had preexisting AF. These patients had increased odds of 90-day all-cause (odds ratio [OR], 2.81; 95% CI, 2.33-3.38) and PE-related mortality (OR, 2.38; 95% CI, 1.37-4.14) and increased 1-year hazard for ischemic stroke (hazard ratio, 5.48; 95% CI, 3.10-9.69) compared with those without AF. After multivariable adjustment, preexisting AF was associated with significantly increased odds of all-cause mortality (OR, 1.91; 95% CI, 1.57-2.32) but not PE-related mortality (OR, 1.50; 95% CI, 0.85-2.66). Among 16 497 patients with PE, 445 developed new incident AF within 2 days of acute PE. Incident AF was associated with increased odds of 90-day all-cause (OR, 2.28; 95% CI, 1.75-2.97) and PE-related (OR, 3.64; 95% CI, 2.01-6.59) mortality but not stroke. Findings were similar in multivariable analyses. Conclusions In patients with acute symptomatic PE, both preexisting AF and incident AF predict adverse clinical outcomes. The type of adverse outcomes may differ depending on the timing of AF onset.info:eu-repo/semantics/publishedVersio

Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19)

Objectives: The objective of this study was to estimate the association between tocilizumab or corticosteroids and the risk of intubation or death in patients with coronavirus disease 19 (COVID-19) with a hyperinflammatory state according to clinical and laboratory parameters. Methods: A cohort study was performed in 60 Spanish hospitals including 778 patients with COVID-19 and clinical and laboratory data indicative of a hyperinflammatory state. Treatment was mainly with tocilizumab, an intermediate-high dose of corticosteroids (IHDC), a pulse dose of corticosteroids (PDC), combination therapy, or no treatment. Primary outcome was intubation or death; follow-up was 21 days. Propensity score-adjusted estimations using Cox regression (logistic regression if needed) were calculated. Propensity scores were used as confounders, matching variables and for the inverse probability of treatment weights (IPTWs). Results: In all, 88, 117, 78 and 151 patients treated with tocilizumab, IHDC, PDC, and combination therapy, respectively, were compared with 344 untreated patients. The primary endpoint occurred in 10 (11.4%), 27 (23.1%), 12 (15.4%), 40 (25.6%) and 69 (21.1%), respectively. The IPTW-based hazard ratios (odds ratio for combination therapy) for the primary endpoint were 0.32 (95%CI 0.22-0.47; p < 0.001) for tocilizumab, 0.82 (0.71-1.30; p 0.82) for IHDC, 0.61 (0.43-0.86; p 0.006) for PDC, and 1.17 (0.86-1.58; p 0.30) for combination therapy. Other applications of the propensity score provided similar results, but were not significant for PDC. Tocilizumab was also associated with lower hazard of death alone in IPTW analysis (0.07; 0.02-0.17; p < 0.001). Conclusions: Tocilizumab might be useful in COVID-19 patients with a hyperinflammatory state and should be prioritized for randomized trials in this situatio

The imaging magnetograph eXperiment for the SUNRISE balloon Antarctica project

13 pages, 8 figures.-- Published in: "Optical, Infrared, and Millimeter Space Telescopes" [Section: Solar], edited by John C. Mather.-- Contributed to the conference with same title, Glasgow, Jun 21, 2004.Final full-text version available Open Access at: http://www.iaa.es/~jti/publications/SPIE2Valentin.pdfThe SUNRISE balloon project is a high-resolution mission to study solar magnetic fields able to resolve the critical scale of 100 km in the solar photosphere, or about one photon mean free path. The Imaging Magnetograph eXperiment (IMaX) is one of the three instruments that will fly in the balloon and will receive light from the 1m aperture telescope of the mission. IMaX should take advantage of the 15 days of uninterrupted solar observations and the exceptional resolution to help clarifying our understanding of thesmall-scale magnetic concentrations that pervade the solar surface. For this, IMaX should act as a diffraction limited imager able to carry out spectroscopic analysis with resolutions in the 50.000-100.000 range and capable to perform polarization measurements. The solutions adopted by the project to achieve all these three demanding goals are explained in this article. They include the use of Liquid Crystal Variable Retarders for the polarization modulation, oneLiNbO3 etalon in double pass and two modern CCD detectors that allow for the application of phase diversity techniques by slightly changing the focus of one of the CCDs.This project is funded by the Spanish Programa Nacional del Espacio under project ESP2003-07735.Peer reviewe

Juan Ramón, el poeta de Moguer

El CEIP Manuel Pérez de Bollullos Par del Condado (Huelva) ha recibido el Primer Premio de Páginas Web Educativas de la Junta de Andalucía, y ha sido galardonado con la Medalla de Oro al Mérito EducativoEl planteamiento de esta unidad didáctica nace porque durante el año 2006 se celebra el cincuenta aniversario de la concesión del Premio Nobel de Literatura al ilustre escritor onubense y del pueblo de Moguer Juan Ramón Jiménez. Se han escogido ciertos capítulos de su famoso libro, Platero y yo, porque trata temas tan cercanos a los niños y niñas como el descubrimiento de la naturaleza, el amor a los animales, el Coto de Doñana, costumbres y fiestas tan próximas como la romería de El Rocío, los Reyes Magos; actividades como la vendimia,... acercando así a un rico y variado vocabulario y dando a conocer un poco más la provincia de Huelva. A partir de estos capítulos se han desarrollado una serie de actividades para así conseguir los objetivos que se han planteado en esta unidad didáctica.AndalucíaCEIP Manuel Pérez; Calle Maestra María Jesús Jiménez, 1; 21710 Bollullos Par del Condado (Huelva); +34959439906; +34959439907; [email protected]

Biodiversidad 2014. Reporte de Estado y Tendencias de la Biodiversidad Continental de Colombia

Biodiversidad 2014 es el resultado de esfuerzos importantes de análisis científico, como también de coordinación nacional de información e inventario sobre la biodiversidad en Colombia y representa un adelanto en la manera de presentar datos sobre el estado de la biodiversidad, su localización y los factores de cambios, presentando escenarios posibles de sus tendencias futuras. Esto implica nuevos enfoques para la gestión ambiental, que puedan aportar nuevas formas de desarrollo que no impliquen la pérdida de las especies o los ecosistemas que habitan.Bogotá, D. C

Clinical Presentation and Short- and Long-term Outcomes in Patients With Isolated Distal Deep Vein Thrombosis vs Proximal Deep Vein Thrombosis in the RIETE Registry

International audienceImportance: Insufficient data exist about the clinical presentation, short-term, and long-term outcomes of patients with isolated distal deep vein thrombosis (IDDVT), that is, thrombosis in infrapopliteal veins without proximal extension or pulmonary embolism (PE).Objective: To determine the clinical characteristics, short-term, and 1-year outcomes in patients with IDDVT and to compare the outcomes in unadjusted and multivariable adjusted analyses with patients who had proximal DVT.Design, setting, and participants: This was a multicenter, international cohort study in participating sites of the Registro Informatizado Enfermedad Tromboembólica (RIETE) registry conducted from March 1, 2001, through February 28, 2021. Patients included in this study had IDDVT. Patients with proximal DVT were identified for comparison. Patients were excluded if they had a history of asymptomatic DVT, upper-extremity DVT, coexisting PE, or COVID-19 infection.Main outcomes and measures: Primary outcomes were 90-day and 1-year mortality, 1-year major bleeding, and 1-year venous thromboembolism (VTE) deterioration, which was defined as subsequent development of proximal DVT or PE.Results: A total of 33 897 patients were identified with isolated DVT (without concomitant PE); 5938 (17.5%) had IDDVT (mean [SD] age, 61 [17] years; 2975 male patients [50.1%]), and 27 959 (82.5%) had proximal DVT (mean [SD] age, 65 [18] years; 14 315 male patients [51.2%]). Compared with individuals with proximal DVT, those with IDDVT had a lower comorbidity burden but were more likely to have had recent surgery or to have received hormonal therapy. Patients with IDDVT had lower risk of 90-day mortality compared with those with proximal DVT (odds ratio [OR], 0.47; 95% CI, 0.40-0.55). Findings were similar in 1-year unadjusted analyses (hazard ratio [HR], 0.52; 95% CI, 0.46-0.59) and adjusted analyses (HR, 0.72; 95% CI, 0.64-0.82). Patients with IDDVT had a lower 1-year hazard of VTE deterioration (HR, 0.83; 95% CI, 0.69-0.99). In 1-year adjusted analyses of patients without an adverse event within the first 3 months, IDDVT was associated with lower risk of VTE deterioration (adjusted HR, 0.48; 95% CI, 0.24-0.97). By 1-year follow-up, symptoms or signs of postthrombotic syndrome were less common in patients with IDDVT (47.6% vs 60.5%).Conclusions and relevance: Results of this cohort study suggest that patients with IDDVT had a less ominous prognosis compared with patients with proximal DVT. Such differences were likely multifactorial, including the differences in demographics, risk factors, comorbidities, particularly for all-cause mortality, and a potential association of thrombus location with VTE deterioration and postthrombotic syndrome. Randomized clinical trials are needed to assess the optimal long-term management of IDDVT